Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | +14.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.24 | N/A | +14.29% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions and emphasized the importance of innovation. They did not provide specific guidance for future quarters.
Management acknowledged the ongoing challenges in the market.
They highlighted the need for continued focus on research and development.
Biocryst Pharmaceuticals reported a loss that was slightly better than expected, but the stock fell by over 7% in reaction. Investors may be concerned about the lack of revenue details and the absence of forward guidance. The management's cautious tone suggests that challenges remain ahead, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WEC ENERGY GROUP INC
May 5, 2009